Mitchell Revill

Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer.

Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer.

Journal: Cell reports
Published: May 24, 2024

Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer.

Functional Characterisation of the ATOH1 Molecular Subtype Indicates a Pro-Metastatic Role in Small Cell Lung Cancer.

Journal: bioRxiv : the preprint server for biology
Published: February 26, 2024

Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.

Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer.

Journal: Nature communications
Published: December 10, 2020

The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.

The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 04, 2020

A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.

A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity.

Journal: Nature cancer
Published: August 14, 2019

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.

Journal: Science translational medicine
Published: December 07, 2016

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Journal: Oncotarget
Published: November 16, 2016

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.

Journal: British journal of cancer
Published: April 25, 2013
Showing 1-8 of 8

Last Updated: 09/26/2026